News
Biocon Biologics secures multiple market access agreements in US for Yesintek
"Yesintek represents an important milestone for Biocon Biologics, as this is the first product we have launched in the United States as a fully integrated biosimilars company," Biocon Biologics CEO & Managing Director Shreehas Tambe said.
Avammune Therapeutics Raises INR 100 Crore in Series A
"This funding validates our extensive preclinical datasets and empowers us to accelerate the development of our lead program into the clinic for addressing critical unmet needs in oncology," said Papaiah, co-founder of Avammune.
.jpg)
'voice for BT' 2025 International (ASEAN)
